[4] Wang M, et al. Sunvozertinib for patients in China with platinum-pretreated locally advanced or metastatic non-small-cell lung cancer and EGFR exon 20 insertion mutation (WU-KONG6): single-arm, open-label,
[5] Kwon C S , Lin H M , Crossland V ,et al.Non-small cell lung cancer with EGFR exon 20 insertion mutation: a systematic literature review and meta-analysis of patient outcomes[J].Current medical research and opinion,...
[1]Wang M,et al.Sunvozertinib for patients in China with platinum-pretreated locally advanced or linkstatic non-small-cell lung cancer and EGFR exon 20 insertion mutation (WU-KONG6): single-arm, open-label, multicentre, phase 2 trial[J]. The Lancet Respiratory Medicine, 2024, 12(3): 2...
Herein we report a case of advanced thymic squamous cell carcinoma harboringEGFRexon 20 insertion in which apatinib was administered after multi‐line chemotherapy and radiotherapy and a partial response was achieved after five months of treatment. To date, a five month overall response and 10 ...
Successful treatment of a lung adenocarcinoma patient with a novel EGFR exon 20-ins mutation with afatinib. journals.lww.com/md-jou 4、Fang W, et al.EGFR exon 20 insertion mutations and response to osimertinib in non-small-cell lung cancer BMC Cancer. 2019 Jun 17;19(1):595. 5、Fang W...
[6]Wang M, Fan Y, Sun M, et al. Sunvozertinib for patients in China with platinum-pretreated locally advanced or metastatic non-small-cell lung cancer and EGFR exon 20 insertion mutation (WU-KONG6): singlearm, open-label, multicentre, phase 2 trial. Lancet Respir Med, 2024, 12(3):...
102605.Mobocertinib May Offer Effective, Safe Treatment in NSCLC with EGFR Exon 20 Insertion Mutation | IASLC.李汶倩,白日兰,崔久嵬.驱动基因阳性肺癌脑转移患者的靶向治疗进展[J].中国肺癌杂志,2019,22(11):719-726.Zhou C,Ramalingam S,Li B,et al.Mobocertinib in NSCLC with EGFR exon 20 ...
21.Wang M, Fan Y, Sun M, et al. Sunvozertinib for patients in China with platinum-pretreated locally advanced or metastatic non-small-cell lung cancer and EGFR exon 20 insertion mutation (WU-KONG6): single-arm, open-label, multicentre, phase 2 trial. Lancet Respir Med. 2024;12(3):...
[4]Simon Wyse, et al.Amivantamab for the treatment of EGFR exon 20 insertion mutant non-small cell lung cancer[J]. Expert Rev Anticancer Ther 2022 Jan:22(1)3-16. [5]Park K, Haura EB, Leighl NB, et al. Amivantamab in EGFR exon 20 insertion-mutated non-small-cell lung cancer pr...
[12]Sabari JK et al.,Amivantamab in post-platinum EGFR exon 20 insertion mutation non-small cell lung cancer.J Thorac Oncol 2021;16(3):S108-S109. [13]Doebele X,Riely GJ,Spira K,et al.First report of safety,PK,and preliminary antitumor activity of the oral EGFR/HER2 exon 20 inhibit...